Jiayuan Wu

Mr. Jiayuan Wu

The key Laboratory, The Second Affiliated Hospital of Jiaxing University

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Cell Death & Disease
Verified
Journal Article
Open access
CGChao Gu
Chao Gu
YZYan Zhang
Yan Zhang
QHQingsong Hu
Qingsong Hu
JWJiayuan Wu
Jiayuan Wu
HRHaigang Ren
Haigang Ren
GWGuanghui Wang
Guanghui Wang
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease. Although its pathogenesis remains unclear, mitochondrial dysfunction plays a vital role in the pathology of PD. P7C3, an aminopropyl carbazole, possesses a significant neuroprotective ability in several neurodegenerative disorders, including PD. Here, we showed that P7C3 stabilized mitochondrial membrane potential, reduced reactive oxygen species production, and inhibited cytochromecrelease in MES23.5 cells (a dopaminergic (DA) cell line) exposed to 1-methyl-4-phenylpyridinium (MPP+). In MES23.5 cells, P7C3 inhibited glycogen synthase kinase-3 beta (GSK3β) activation induced by MPP+. P7C3 also inhibited p53 activity and repressed Bax upregulation to protect cells from MPP+toxicity. In addition, the activation of p53 was significantly attenuated with the inhibition of GSK3βactivity by P7C3. Furthermore, P7C3 blocked GSK3βand p53 activation in the midbrain, and prevented DA neuronal loss in the substantia nigra in 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine mice. Thus, our study demonstrates that P7C3 protects DA neurons from neurotoxin-induced cell death by repressing the GSK3β-p53-Bax pathway bothin vitroandin vivo, thus providing a theoretical basis for P7C3 in the potential clinical treatment of PD.

24 August 2015 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
JWJiayuan Wu
Jiayuan Wu
MLMei Li
Mei Li
LCLi-Juan Cao
Li-Juan Cao
MSMei-Ling Sun
Mei-Ling Sun
DCDong Chen
Dong Chen
GWGuanghui Wang
Guanghui Wang

5 November 2018 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
CGChao Gu
Chao Gu
QHQingsong Hu
Qingsong Hu
JWJiayuan Wu
Jiayuan Wu
CMChenchen Mu
Chenchen Mu
HRHaigang Ren
Haigang Ren
GWGuanghui Wang
Guanghui Wang
Parkinson’s disease (PD) is the second most common neurodegenerative disorder. Although its pathogenesis remains unclear, growing evidencce suggests that microglia-mediated neuroinflammation contributes greatly to the progression of PD. P7C3, an aminopropyl carbazole, possesses significant neuroprotective effects in several neurodegenerative disease animal models, including PD. In this study, we designed to investigate the effects of P7C3 on neuroinflammation. We showed that P7C3 specially suppressed the expression of lipopolysaccharide (LPS)-induced pro-inflammatory factors but not influenced the anti-inflammatory factors in microglia. The inhibition of the nuclear factor κB (NF-κB) signaling pathway was involved in the mechanisms of the anti-inflammatory effects by P7C3. LPS-induced activation of IκB kinase (IKK), degradation of the inhibitory κB alpha (IκBα) and nuclear translocation of NF-κB can be attenuated by the pretreatment of P7C3 in microglia. Furthermore, in LPS-treated microglia, P7C3-pretreatment decreased the toxicity of conditioned media to MES23.5 cells (a dopaminergic (DA) cell line). Most importantly, the anti-inflammatory effects of P7C3 were observed in LPS-stimulated mouse model. In general, our study demonstrates that P7C3 inhibits LPS-induced microglial activation through repressing the NF-κB pathway both in vivo and in vitro, providing a theoretical basis for P7C3 in anti-inflammation.

15 November 2019 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ZLZheng Li
Zheng Li
JWJiayuan Wu
Jiayuan Wu
JMJuanfen Mo
Juanfen Mo
LGLi Guo
Li Guo
XWXiaoyan Wu
Xiaoyan Wu
YBYi Bao
Yi Bao
Polydatin (PD), an active component of Chinese herbs, is reported to have many biological functions, such as cardioprotective actions, anti-inflammatory activities, and antitumor effects. In this study, we investigated the effects of PD on body weight control, glucose and lipid metabolic regulation, and anti-inflammation in a high-fat-diet- (HFD-) induced obese mice model. After treatment of PD (100 mg/kg/d for 4 weeks), HFD mice reduced body weight, retroperitoneal fat mass, and adipose cell sizes; significantly lowered serum total cholesterol triglyceride (TG) and low-density lipoprotein (LDL) levels; and increased high-density lipoprotein (HDL) levels compared with the HFD control mice. Further studies showed that PD downregulated the mRNA and protein expressions of peroxisome proliferator-activated receptor gamma (PPARγ), a transcription factor involving in the regulation of adipocyte differentiation, in the retroperitoneal fat of HFD mice. Additionally, PD significantly upregulated the mRNA and protein expressions of leptin, an adipocyte-derived anorexic hormone that regulates food intake and energy expenditure, in the adipose tissues of HFD mice. Moreover, PD reduced the expression levels of monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF-α) in the retroperitoneal and epididymal tissues of HFD mice, suggesting that PD prevented adipose tissue inflammation. In conclusion, PD may serve as a pharmaceutic candidate for obesity-related lipid metabolism, anti-inflammation, and body weight loss.

5 July 2022 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
JMJuanfen Mo
Juanfen Mo
ZGZhenzhen Gao
Zhenzhen Gao
LZLi Zheng
Li Zheng
MYMiaolong Yan
Miaolong Yan
MXMin Xue
Min Xue
JWJiayuan Wu
Jiayuan Wu
Metabolic remodeling is the fundamental molecular feature of malignant tumors. Cancer cells require sufficient energy supplies supporting their high proliferative rate. MTHFD2, a mitochondrial one-carbon metabolic enzyme, is dysregulated in several malignancies and may serve as a promising therapeutic candidate in cancer treatment. Here, our data confirmed that MTHFD2 gene and protein was upregulated in the cancerous tissues of LUAD patients and was correlated with a poor survival in LUAD. MTHFD2 was involved in lung cancer cell proliferation, migration, and apoptosis by mediating its downstream molecules, such as DNA helicases (MCM4 and MCM7), as well as ZEB1, Vimentin and SNAI1, which contributed to tumor cell growth and epithelial-to-mesenchymal transition (EMT) process. Moreover, we identified that miRNA-99a-3p appeared to be an upstream mediator directly regulating MTHFD2 and MCM4 expression. Moreover, specific inhibition of MTHFD2 functions by siRNA or a chemical compound, improved anti-tumor sensitivities induced by pemetrexed in LUAD. Taken together, our study revealed the underlying molecular mechanisms of MTHFD2 in regulating cell proliferation and identified a novel therapeutic strategy improving the treatment efficacies in LUAD.

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
JWJiayuan Wu
Jiayuan Wu
ZLZheng Li
Zheng Li
JMJuanfen Mo
Juanfen Mo
XYXiujuan Yao
Xiujuan Yao
CFChenliang Fan
Chenliang Fan
YBYi Bao
Yi Bao
MitoTEMPO, a mitochondrial antioxidant, has protective effects on liver‐related diseases. However, the role of MitoTEMPO on nonalcoholic fatty liver disease (NAFLD) and its possible mechanisms are largely unknown. Here, we investigated the effects of MitoTEMPO on NAFLD using high fat diet‐ (HFD‐) induced obese mice as animal models. MitoTEMPO was intraperitoneally injected into HFD mice. Liver morphological changes were observed by H&E and Oil Red O staining, and the frequency of MDSCs in peripheral blood was analyzed by flow cytometry. Moreover, real‐time quantitative PCR, western blot, and immunohistochemistry were conducted to detect the mRNA and protein expressions in the liver tissues. The results showed that the hepatic steatosis in liver tissues of HFD mice injected with MitoTEMPO was significantly ameliorated. Additionally, MitoTEMPO reduced the frequency of CD11b+Gr‐1+ MDSCs in peripheral circulation and decreased Gr‐1+ cell accumulation in the livers. Further studies demonstrated that MitoTEMPO administration suppressed the mRNA and protein expressions of MDSC‐associated proinflammatory mediators, such as monocyte chemoattractant protein‐1 (MCP‐1), S100 calcium‐binding protein A8 (S100A8), and S100 calcium‐binding protein A9 (S100A9). Our results suggest that MitoTEMPO appears to be a potential chemical compound affecting certain immune cells and further ameliorates inflammation in obese‐associated NAFLD.